Nivolumab Improves Survival in Phase III Head and Neck Cancer Study
Nivolumab has improved overall survival versus investigator's choice of therapy for patients with platinum‑refractory squamous cell carcinoma of the head and neck in the phase III CheckMate‑141 trial.
In the phase III CheckMate‑141 trial, nivolumab (Opdivo) significantly improved overall survival versus investigator‑choice therapies (cetuximab, methotrexate, or docetaxel) in patients with platinum‑refractory squamous cell carcinoma of the head and neck.
The findings support nivolumab as a new therapeutic option for a disease with high unmet need and limited treatment alternatives, potentially extending patient survival.
Bizonyítékszint: Állatkísérletes. Állatmodellben vizsgálták.
Kapcsolódó jelek
- Spatial Profiling of the Head and Neck Squamous Cell Carcinoma Microenvironment: Reshaping Our Understanding and Therapeutic Opportunities
- Understanding and overcoming innate and acquired MAPK inhibition resistance in anaplastic thyroid cancer
- Review Systemic therapy in the curative treatment of head and neck squamous cell cancer: a systematic review
- Preclinical models in head and neck squamous cell carcinoma
- CAR-Based Cell Therapy in Head and Neck Cancer: A Comprehensive Review on Clinical Applicability